1. Approval of Re-appointment of Mr. Arvind Vilasrao Sapkal[DIN: 08607096] as a non-executive independent director of the company for his second term of 5 (Five) years. 2. Approval of ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
At the 32nd Annual General Meeting held on September 29, 2025, shareholders of Ishita Drugs & Industries approved three key items. First, Mr. Arvind Vilasrao Sapkal (DIN: 08607096), a Mechanical Engineer from IIT Mumbai with 33+ years of experience in the Oil & Gas industry, was re-appointed as a Non-Executive Independent Director for a second term of 5 years, effective October 1, 2025 to September 30, 2030. Second, M/s Meenu Maheshwari & Associates was appointed as Secretarial Auditor for a 5-year term covering FY 2025-26 to FY 2029-30. Third, M/s Jaymin Shah & Associates (FRN: 129406W) was re-appointed as Statutory Auditor for 1 year, until the conclusion of the 33rd AGM.
These are routine governance and compliance-related re-appointments approved by shareholders, with no changes to company strategy or operations. Investors should see this as standard regulatory housekeeping with no material impact on the stock price.